First, we studied almost 20 times more CHD patients than the previous largest study of loss-of-function PLA2G7 alleles, thereby providing the first robust genetic evaluation of effect sizes of Lp-PLA2 inhibition relevant to phase 3 trials such as relative risk reductions for CHD of 20%. The gene discussed is PLA2G7; the disease is coronary artery disorder.